tetano
Editor, Senior Moderator
Infect Dis Poverty
. 2022 May 16;11(1):56.
doi: 10.1186/s40249-022-00982-0.
COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status
Zhujun Cao[SUP] #[/SUP][SUP] 1 [/SUP], Chenxi Zhang[SUP] #[/SUP][SUP] 1 2 [/SUP], Shuang Zhao[SUP] 1 [/SUP], Zike Sheng[SUP] 1 [/SUP], Xiaogang Xiang[SUP] 1 [/SUP], Ruokun Li[SUP] 3 [/SUP], Zhuping Qian[SUP] 1 4 [/SUP], Yinling Wang[SUP] 1 5 [/SUP], Bin Chen[SUP] 1 6 [/SUP], Ziqiang Li[SUP] 1 [/SUP], Yuhan Liu[SUP] 1 [/SUP], Baoyan An[SUP] 1 [/SUP], Huijuan Zhou[SUP] 1 [/SUP], Wei Cai[SUP] 1 [/SUP], Hui Wang[SUP] 1 [/SUP], Honglian Gui[SUP] 1 [/SUP], Haiguang Xin[SUP] 7 [/SUP], Qing Xie[SUP] 8 [/SUP]
Affiliations
Abstract
Background: Safety data reported from the large-scale clinical trials of the coronavirus disease 2019 (COVID-19) vaccine are extremely limited in patients with decompensated cirrhosis. The vaccination campaign in this specific population could be difficult due to uncertainty about the adverse events following vaccination. We aimed to assessed the COVID-19 vaccination rate, factors associated with unvaccinated status, and the adverse events following vaccination in patients with decompensated cirrhosis.
Methods: This is a retrospective study from Ruijin Hospial (Shanghai, China) on an ongoing prospective cohort designed for long-term survival analysis of decompensated cirrhotic patients who recovered from decompensating events or acute-on-chronic liver failure (ACLF) between 2016 and 2018. We assessed the COVID-19 vaccination rate, the number of doses, type of vaccine, safety data, patient-reported reasons for remaining unvaccinated, factors associated with unvaccinated status, and the adverse events of COVID-19 vaccine. Binary logistic regression was used for identifying factors associated with unvaccinated status.
Results: A total of 229 patients with decompensated cirrhosis without previous SARS-CoV-2 infection participated (mean age, 56 ± 12.2 years, 75% male, 65% viral-related cirrhosis). Mode of decompensation were grade II‒III ascites (82.5%), gastroesophageal varices bleeding (7.9%), hepatic encephalopathy (7.9%). Eighty-five participants (37.1%) received at least one dose of vaccination (1 dose: n = 1, 2 doses: n = 65, 3 doses: n = 19) while 62.9% remained unvaccinated. Patient-reported reasons for remaining unvaccinated were mainly fear of adverse events (37.5%) and lack of positive advice from healthcare providers (52.1%). The experience of hepatic encephalopathy (OR = 5.61, 95% CI: 1.24-25.4) or ACLF (OR = 3.13, 95% CI: 1.12-8.69) and post-liver transplantation status (OR = 2.47, 95% CI: 1.06-5.76) were risk factors of remaining unvaccinated independent of residential areas. The safety analysis demonstrated that 75.3% had no adverse events, 23.6% had non-severe reactions (20% injection-site pain, 1.2% fatigue, 2.4% rash) and 1.2% had a severe event (development of acute decompensation requiring hospitalization).
Conclusions: Patients with decompensated cirrhosis in eastern China are largely remained at unvaccinated status, particularly those with previous episodes of ACLF or hepatic encephalopathy and liver transplantation recipients. Vaccination against COVID-19 in this population is safe.
Keywords: Acute-on-chronic liver failure; COVID-19; Decompensated cirrhosis; Liver transplantation; SARS-CoV-2; Vaccine.
. 2022 May 16;11(1):56.
doi: 10.1186/s40249-022-00982-0.
COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status
Zhujun Cao[SUP] #[/SUP][SUP] 1 [/SUP], Chenxi Zhang[SUP] #[/SUP][SUP] 1 2 [/SUP], Shuang Zhao[SUP] 1 [/SUP], Zike Sheng[SUP] 1 [/SUP], Xiaogang Xiang[SUP] 1 [/SUP], Ruokun Li[SUP] 3 [/SUP], Zhuping Qian[SUP] 1 4 [/SUP], Yinling Wang[SUP] 1 5 [/SUP], Bin Chen[SUP] 1 6 [/SUP], Ziqiang Li[SUP] 1 [/SUP], Yuhan Liu[SUP] 1 [/SUP], Baoyan An[SUP] 1 [/SUP], Huijuan Zhou[SUP] 1 [/SUP], Wei Cai[SUP] 1 [/SUP], Hui Wang[SUP] 1 [/SUP], Honglian Gui[SUP] 1 [/SUP], Haiguang Xin[SUP] 7 [/SUP], Qing Xie[SUP] 8 [/SUP]
Affiliations
- PMID: 35578350
- DOI: 10.1186/s40249-022-00982-0
Abstract
Background: Safety data reported from the large-scale clinical trials of the coronavirus disease 2019 (COVID-19) vaccine are extremely limited in patients with decompensated cirrhosis. The vaccination campaign in this specific population could be difficult due to uncertainty about the adverse events following vaccination. We aimed to assessed the COVID-19 vaccination rate, factors associated with unvaccinated status, and the adverse events following vaccination in patients with decompensated cirrhosis.
Methods: This is a retrospective study from Ruijin Hospial (Shanghai, China) on an ongoing prospective cohort designed for long-term survival analysis of decompensated cirrhotic patients who recovered from decompensating events or acute-on-chronic liver failure (ACLF) between 2016 and 2018. We assessed the COVID-19 vaccination rate, the number of doses, type of vaccine, safety data, patient-reported reasons for remaining unvaccinated, factors associated with unvaccinated status, and the adverse events of COVID-19 vaccine. Binary logistic regression was used for identifying factors associated with unvaccinated status.
Results: A total of 229 patients with decompensated cirrhosis without previous SARS-CoV-2 infection participated (mean age, 56 ± 12.2 years, 75% male, 65% viral-related cirrhosis). Mode of decompensation were grade II‒III ascites (82.5%), gastroesophageal varices bleeding (7.9%), hepatic encephalopathy (7.9%). Eighty-five participants (37.1%) received at least one dose of vaccination (1 dose: n = 1, 2 doses: n = 65, 3 doses: n = 19) while 62.9% remained unvaccinated. Patient-reported reasons for remaining unvaccinated were mainly fear of adverse events (37.5%) and lack of positive advice from healthcare providers (52.1%). The experience of hepatic encephalopathy (OR = 5.61, 95% CI: 1.24-25.4) or ACLF (OR = 3.13, 95% CI: 1.12-8.69) and post-liver transplantation status (OR = 2.47, 95% CI: 1.06-5.76) were risk factors of remaining unvaccinated independent of residential areas. The safety analysis demonstrated that 75.3% had no adverse events, 23.6% had non-severe reactions (20% injection-site pain, 1.2% fatigue, 2.4% rash) and 1.2% had a severe event (development of acute decompensation requiring hospitalization).
Conclusions: Patients with decompensated cirrhosis in eastern China are largely remained at unvaccinated status, particularly those with previous episodes of ACLF or hepatic encephalopathy and liver transplantation recipients. Vaccination against COVID-19 in this population is safe.
Keywords: Acute-on-chronic liver failure; COVID-19; Decompensated cirrhosis; Liver transplantation; SARS-CoV-2; Vaccine.